Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1086 participants
OBSERVATIONAL
2017-09-05
2022-03-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. Planned registration period 2 years
2. Planned surveillance period for 4 years from 6 months after launch
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison of Otezla to SFA-002 to Placebo in Plaque Psoriasis Patients
NCT06863493
Study to Evaluate Safety and Efficacy of Oral MP1032 in Psoriasis Patients
NCT02908347
A Study of Otezla® in Patients With Plaque Psoriasis Under Routine Conditions
NCT02626793
A Study of the Real-life Management of Psoriasis Patients Treated With Otezla® (Apremilast) in Belgium
NCT03097003
Study to Assess the Efficacy and Safety of Orismilast in Psoriasis
NCT05190419
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with PsV and PsA treated with OTEZLA Tablets
Patients with psoriasis vulgaris and patients with psoriatic arthritis who are treated with OTEZLA Tablets
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Psoriasis vulgaris that is with an inadequate response to topical therapies
* Psoriasis arthropathica
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Amgen
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
MD
Role: STUDY_DIRECTOR
Amgen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tugi dermatology clinic
Kitakyushu, Fukuoka, Japan
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Ohtsuki M, Okubo Y, Saeki H, Igarashi A, Imafuku S, Abe M, Chaudhari S, Yaguchi M, Emoto A, Morita A. Safety and effectiveness of apremilast in Japanese patients with psoriatic disease: Results of a post-marketing surveillance study. J Dermatol. 2024 Jul;51(7):950-963. doi: 10.1111/1346-8138.17270. Epub 2024 May 22.
Ohtsuki M, Okubo Y, Saeki H, Igarashi A, Imafuku S, Abe M, Saito K, Ogawa R, Morita A. Clinical Characteristics and Safety Profiles of Japanese Psoriasis Patients Who Continued Apremilast Treatment for 6 and 12 Months: A Post Hoc Analysis of an Apremilast Postmarketing Surveillance Study. J Dermatol. 2025 Jun;52(6):1059-1065. doi: 10.1111/1346-8138.17764. Epub 2025 May 10.
Related Links
Access external resources that provide additional context or updates about the study.
AmgenTrials clinical trials website
Expanded Access for CC-10004
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CC-10004-PSOR-018
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.